Overview

Regorafenib + Panitumumab for Colorectal Cancers

Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety of regorafenib and panitumumab
Phase:
Phase 1
Details
Lead Sponsor:
University of Utah
Treatments:
Antibodies, Monoclonal
Panitumumab